CBIO - Catalyst Biosciences, Inc.
| Previous Close | 8.43 |
| Open | 8.43 |
| Bid | 8.47 x 1000 |
| Ask | 8.49 x 900 |
| Day's Range | 8.29 - 8.49 |
| 52 Week Range | 6.20 - 11.44 |
| Volume | 30,054 |
| Avg. Volume | 218,996 |
| Market Cap | 100.677M |
| Beta (3Y Monthly) | 2.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.35 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2015-08-20 |
| 1y Target Est | 24.30 |
- Benzinga•10 days ago
A Look At Benzinga Pro's Most-Searched Tickers For July 8, 2019
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Sangamo Therapeutics, Inc . (NASDAQ: SGMO ...
- Simply Wall St.•16 days ago
If You Had Bought Catalyst Biosciences (NASDAQ:CBIO) Stock Three Years Ago, You'd Be Sitting On A 68% Loss, Today
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
- GlobeNewswire•17 days ago
Catalyst Biosciences Announces Oral and Poster Presentations at the International Society on Thrombosis and Haemostasis
Oral presentation of the final Phase 2 trial data of MarzAA for the treatment of hemophilia A or B with inhibitors Company to host investor call and webcast on Monday, July 8.
- GlobeNewswire•2 months ago
Catalyst Biosciences to Present at the Jefferies 2019 Global Healthcare Conference
Catalyst Biosciences, Inc. (CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Biosciences, will present a corporate overview at the Jefferies 2019 Global Healthcare Conference at 2:30 p.m. EDT on Tuesday, June 4, 2019 in New York. Catalyst is a clinical-stage biopharmaceutical company focused on developing novel medicines to address serious medical conditions for individuals who need new or better treatment options.
- GlobeNewswire•3 months ago
Catalyst Biosciences Reports First Quarter 2019 Operating & Financial Results and Provides a Corporate Update
Final MarzAA Phase 2 data to be presented at upcoming International Society for Thrombosis & Hemostasis (ISTH) meeting in July 2019 MarzAA Orphan Drug Designation.
- GlobeNewswire•3 months ago
Catalyst Biosciences & Mosaic Biosciences Present Preclinical Data on Pegylated CB 2782 for the Treatment of Dry Age-Related Macular Degeneration
Catalyst Biosciences, Inc. (CBIO), and Mosaic Biosciences today announced the presentation of new data on pegylated CB 2782 (CB 2782-PEG), Catalyst’s preclinical anti-C3 candidate being developed for the treatment of geographic atrophy (GA) associated dry age-related macular degeneration (dry AMD) at the 2019 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), being held in Vancouver, British Columbia, from April 28 - May 2, 2019. The poster, entitled: “Pegylated CB 2782: A Complement Factor C3-Inactivating Protease and Potential Long-Acting Treatment for Dry AMD,” was presented by Eric Furfine, Ph.D., Mosaic’s Head of Ophthalmology.
- GlobeNewswire•3 months ago
Catalyst Biosciences to Present at The Needham & Company 18th Annual Healthcare Conference
Catalyst Biosciences, Inc. (CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer, will present a corporate overview at the Needham & Company 18th Annual Healthcare Conference at 12:50 p.m. EDT on Tuesday, April 9, 2019 at the Westin Grand Central Hotel in New York. An archived webcast of the presentation can be accessed for 90 days from the Events and Presentations section on the Company’s website.
- GlobeNewswire•4 months ago
Catalyst Biosciences Initiates a Phase 2b Trial of Dalcinonacog Alfa for the Treatment of Hemophilia B
Catalyst Biosciences, Inc. (CBIO), today announced the initiation of enrollment in a Phase 2b study of dalcinonacog alfa (DalcA), a next-generation subcutaneously (SQ) administered Factor IX (FIX) therapy being developed for the treatment of hemophilia B. “The data from our Phase 1/2 clinical study demonstrated that DalcA is highly efficacious for the treatment of hemophilia B and can achieve Factor IX activity levels well above the 12% expected to prevent spontaneous bleeding,” said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. “We anticipate that this Phase 2b study will further demonstrate DalcA’s safety and efficacy as a subcutaneous prophylactic treatment option.
- Simply Wall St.•4 months ago
Could The Catalyst Biosciences, Inc. (NASDAQ:CBIO) Ownership Structure Tell Us Something Useful?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you want to know who really controls Catalyst Biosciences, Inc. (NASDAQ:CBIO), then you'll have to look at the makeup of i...
- GlobeNewswire•4 months ago
Catalyst Biosciences Receives Orphan Designation from the European Commission for Marzeptacog Alfa (Activated)
Catalyst Biosciences, Inc. (CBIO) today announced that the European Commission has awarded orphan designation of its Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA) for the treatment of haemophilia B (with or without inhibitors). Catalyst has also completed dosing in the Phase 2 portion of the Phase 2/3 subcutaneous trial of MarzAA for the treatment of hemophilia A or B with inhibitors.
- GuruFocus.com•4 months ago
Catalyst Biosciences Inc (CBIO) Files 10-K for the Fiscal Year Ended on December 31, 2018
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is engaged in creating and developing novel medicines to address serious medical conditions. Catalyst Biosciences Inc had annual average EBITDA growth of 33.50% over the past five years.For the latest fiscal year the company reported a revenue of $0.01 million, a decrease of 99.4% from the previous year.
- GlobeNewswire•4 months ago
Catalyst Biosciences Reports Fourth Quarter and Full-Year 2018 Operating & Financial Results and Provides a Corporate Update
Completed enrollment of the MarzAA SQ Phase 2 trial and demonstrated safety and clinical efficacy, with 90% reduction in bleeding Completed a full immunogenicity analysis.
- GlobeNewswire•4 months ago
Catalyst Biosciences Announces Poster Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 06, 2019 -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to.
- GlobeNewswire•5 months ago
New Research: Key Drivers of Growth for Omega Healthcare Investors, Cinedigm, Cardiovascular, Allegiant Travel, Catalyst Biosciences, and ESCO Technologies — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•5 months ago
Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
Catalyst Biosciences, Inc. (CBIO), presented updated interim data from the Phase 2/3 trial of subcutaneous prophylactic Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA) currently being developed for the treatment of hemophilia A or B with inhibitors. “The positive data from our clinical trial demonstrate clinical proof-of-concept for MarzAA as a subcutaneous treatment option for individuals with hemophilia A or B with inhibitors,” said Dr. Nassim Usman, chief executive officer of Catalyst. “To date, each participant in the trial has experienced a clinically significant reduction in annualized bleed rate and the percentage of days with bleeding, highlighting the potential for MarzAA as a safe and effective subcutaneous treatment to reduce spontaneous bleed rates and improve the quality of life of affected individuals.
- GlobeNewswire•5 months ago
Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B
Results show a four-fold reduction in bleeding time for CB 2679d-GT and a three-fold improvement in clotting activity when compared with an AAV-encoding Padua vector Data.
- GlobeNewswire•5 months ago
Catalyst Biosciences to Present at the Annual BIO CEO & Investor Conference
Catalyst Biosciences, Inc., (CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that Nassim Usman, Ph.D., president and chief executive officer, will present a corporate overview at the Annual BIO CEO & Investor Conference, being held in New York City on February 11-12, 2019. To schedule a meeting with the Catalyst Biosciences management team at this conference, please contact LifeSci Advisors. Catalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications.
- GlobeNewswire•6 months ago
Catalyst Biosciences Announces Oral and Poster Presentations at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders
Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced oral and poster presentations at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) being held in Prague from February 6-8, 2019. Dr. Howard Levy, chief medical officer of Catalyst, will deliver an oral presentation on the most up to date data from the Company’s ongoing Phase 2/3 trial of marzeptacog alfa (activated) (MarzAA) for the treatment of hemophilia A or B with inhibitors.
- Simply Wall St.•6 months ago
Is Catalyst Biosciences, Inc.’s (NASDAQ:CBIO) Balance Sheet A Threat To Its Future?
Catalyst Biosciences, Inc. (NASDAQ:CBIO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CBIO Read More...
- Zacks•6 months ago
Zacks.com featured expert Kevin Matras highlights: Net Lease, K12, Brookline Bancorp, Catalyst Biosciences and Knoll
Zacks.com featured expert Kevin Matras highlights: Net Lease, K12, Brookline Bancorp, Catalyst Biosciences and Knoll
- Zacks•6 months ago
These 5 Stocks Make Great Buys on New Analyst Coverage
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
- GlobeNewswire•7 months ago
Catalyst Biosciences Hosts Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs
Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, is hosting a Research & Development (R&D) Day today in New York to provide updates on its Factor IX (FIX) dalcinonacog alfa (DalcA) and Factor VIIa (FVIIa) marzeptacog alfa (activated) (MarzAA) hemophilia programs. A live and archived webcast of the event may be accessed here and on the Events and Presentations section of the Catalyst website.
- GlobeNewswire•7 months ago
Catalyst Biosciences to Host a Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs
Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that it will host a Research and Development Day focusing on the Company’s Factor VIIa and Factor IX hemophilia programs on Tuesday, December 18, from 12:00-2:00 p.m. EST at the Lotte New York Palace. Catalyst Biosciences' management team will provide an update on the Company’s ongoing clinical development work with marzeptacog alfa (activated) (MarzAA), a high potency engineered Factor VIIa for the potential subcutaneous prophylactic treatment of hemophilia A or B with inhibitors, and Factor IX, dalcinonacog alfa (DalcA, formerly known as CB 2679d/ISU304) for the potential subcutaneous prophylactic treatment of hemophilia B. The Company recently announced updated positive interim data from its Phase 2/3 study of MarzAA, which was presented at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition on December 1, 2018.
- GlobeNewswire•8 months ago
Catalyst Biosciences Announces Updated Positive Interim Data from Its Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors
Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced additional positive interim data from its Phase 2/3 study of subcutaneous prophylactic Factor VIIa (FVIIa) variant marzeptacog alfa (activated) (MarzAA), currently being developed for the treatment of hemophilia A or B with inhibitors. The data were presented in a poster at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition on December 1, 2018 in San Diego. “These results support the efficacy of MarzAA as a subcutaneous prophylactic treatment option for individuals with hemophilia A or B with inhibitors,” said Nassim Usman, Ph.D., chief executive officer of Catalyst.
- Simply Wall St.•8 months ago
What Did Catalyst Biosciences Inc’s (NASDAQ:CBIO) CEO Take Home Last Year?
Nassim Usman became the CEO of Catalyst Biosciences Inc (NASDAQ:CBIO) in 2015. First, this article will compare CEO compensation with compensation at similar sized companies. Then we’ll look at a Read More...
